AngelaDispenzieriMD

PubMed

• Cryoablation for unresectable unicentric Castleman disease.
  Yoshito Nishimura, Thomas Atwell, Matthew Callstrom, Patrick McGarrah, Matthew Howard
  American Journal of Hematology. 2025-01-01
• Retreatment of multiple myeloma with previously refractory drugs.
  Utkarsh Goel, Charalampos Charalampous, Prashant Kapoor, Moritz Binder, Francis K Buadi
  Blood Advances. 2024-12-24
• 1 citations
  Prognostic impact of cytogenetic abnormalities detected by FISH in AL amyloidosis with daratumumab-based frontline therapy.
  Rajshekhar Chakraborty, Saurabh Zanwar, Ute Hegenbart, Divaya Bhutani, Morie A Gertz
  Blood. 2024-12-19

Journal Articles

• Systemic Amyloidosis Recognition, Prognosis, and Therapy  
  Morie A Gertz, Angela Dispenzieri, JAMA
• Impact of Prior Diagnosis of Monoclonal Gammopathy on Outcomes in Newly Diagnosed Multiple Myeloma  
  S Vincent Rajkumar, Yi L Hwa, Wilson I Gonsalves, Francis K Buadi, Angela Dispenzieri, Prashant Kapoor, Miriam A Hobbs, Martha Q Lacy, John A Lust, Robert A Kyle, Mori..., Nature
• Safety and Efficacy of Propylene Glycol-Free Melphalan as Conditioning in Patients with AL Amyloidosis Undergoing Stem Cell Transplantation  
  Nelson Leung, Prashant Kapoor, Taxiarchis V Kourelis, Eli Muchtar, Angela Dispenzieri, M Hasib Sidiqi, Martha Q Lacy, Wilson I Gonsalves, Shaji K Kumar, Mohammed A Alj..., Nature
• Relapse After Complete Response in Newly Diagnosed Multiple Myeloma: Implications of Duration of Response and Patterns of Relapse  
  Angela Dispenzieri, Francis K Buadi, Morie A Gertz, Martha Q Lacy, Nelson Leung, Amie L Fonder, Wilson I Gonsalves, Yi Lisa Hwa, Taxiarchis Kourelis, Surbhi Sidana, Ro..., Nature
• Primary Systemic Amyloidosis in Patients with Waldenström Macroglobulinemia  
  Angela Dispenzieri, Eli Muchtar, Ronald Go, Saurabh Zanwar, Surbhi Sidana, Francis Buadi, Stephen M Ansell, Prashant Kapoor, David Dingli, Thomas Habermann, Shaji Kuma..., Nature
• Daratumumab-Based Therapy in Patients with Heavily-Pretreated AL Amyloidosis  
  Saurabh Zanwar, Angela Dispenzieri, Wilson Gonsalves, David Dingli, Jithma P Abeykoon, Martha Q Lacy, Shaji Kumar, Nelson Leung, Morie A Gertz, Eli Muchtar, Francis Bu..., Nature
• Optimizing Deep Response Assessment for AL Amyloidosis Using Involved Free Light Chain Level at End of Therapy: Failure of the Serum Free Light Chain Ratio  
  Morie A Gertz, David Dingli, Miriam Hobbs, John A Lust, Ronald S Go, Amie Fonder, Yi Lin, Shaji K Kumar, Prashant Kapoor, Taxiarchis V Kourelis, S Vincent Rajkumar, Ro..., Nature
• Comparable Outcomes Using Propylene Glycol-Free Melphalan for Autologous Stem Cell Transplantation in Multiple Myeloma  
  Morie A Gertz, Shaji K Kumar, Martha Q Lacy, Prashant Kapoor, Suzanne R Hayman, Robert C Wolf, William J Hogan, Wilson I Gonsalves, Angela A Dispenzieri, David Dingli,..., Nature
• International, Evidence-Based Consensus Treatment Guidelines for Idiopathic Multicentric Castleman Disease  
  Aaron Goodman, Corey Casper, Sudipto Mukherjee, Peter Voorhees, Angela Dispenzieri, David C Fajgenbaum, Amy Chadburn, Razelle Kurzrock, Raj Jayanthan, Sunita Nasta, Th..., Blood
• Utilization of Hematopoietic Stem Cell Transplantation for the Treatment of Multiple Myeloma: A Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consen...  
  John A Lust, Shaji K Kumar, Morie A Gertz, P Leif Bergsagel, Angela Dispenzieri, Francis K Buadi, Prashant Kapoor, Angela A Mayo, Wilson I Gonsalves, Rafael Fonseca, R..., Nature
• Assay to Rapidly Screen for Immunoglobulin Light Chain Glycosylation: A Potential Path to Earlier AL Diagnosis for a Subset of Patients  
  Angela Dispenzieri, MD, Nature
• A Universal Solution for Eliminating False Positives in Myeloma Due to Therapeutic Monoclonal Antibody Interference  
  David L Murray, Angela Dispenzieri, Blood
• Monoclonal Gammopathy of Clinical Significance: A Novel Concept with Therapeutic Implications  
  Robert A Kyle, Nelson Leung, Angela Dispenzieri, Blood
• De Novo Multiple Myeloma after Kidney Transplantation  
  Safadi S, Leung N, Cosio F, Amer H, Gertz M, Rajkumar V, Hayman S, Lacy M, Dispenzieri A, Am J Kidney Dis, 5/1/2014
• Clinical Epidemiology and Treatment Patterns of Patients with Multicentric Castleman Disease: Results from Two Us Treatment Centres  
  Robinson D Jr, Reynolds M, Casper C, Dispenzieri A , Vermeulen J, Payne K, Schramm J, Ristow K, Desrosiers MP, Yeomans K, Teltsch D, Swain R, Habermann TM, Rotella P, ..., Br J Haematol, 4/1/2014
• S0120 Gems: Genomics Encounters MGUS and SMM  
  Dispenzieri A, Blood, 1/2/2014
• Erratum: Long-term Outcome of Patients with Multiple Myeloma-related Advanced Renal Failure following Auto-SCT (Bone Marrow Transplantation (2014) 49 (996) DOI:101038/...  
  Glavey SV, Gertz MA, Dispenzieri A , Kumar S, Buadi F, Lacy M, Hayman SR, Kapoor P, Dingli D, McCurdy A, Hogan WJ, Gastineau DA, Leung N, Bone Marrow Transplant, 1/1/2014
• A Review of Poems Syndrome  
  Dispenzieri A , Buadi FK, Oncology-New York, 12/1/2013
• Outcomes of Pacing in Patients with Cardiac Amyloidosis - A Single Center Experience  
  Hai JJ, Webster TL, Lin G, Dispenzieri A , Grogan M, Brady PA, Circulation, 11/26/2013
• Serum Immunoglobulin Free Light Chains and Rheumatoid Arthritis: A Population-based Study  
  Davis JM, Rajkumar SV, Crowson CS, Deng XL, Dispenzieri A , Larson DR, Therneau TM, Matteson EL, Kyle RA, Katzmann J, Gabriel SE, Arthritis Rheum, 10/1/2013
• Prediction of Poor Mobilization of Autologous Cd34+cells in Multiple Myeloma (MM): Implications for Risk-stratification  
  Costa LJ, Nista EJ, Buadi FK, Lacy MQ, Dispenzieri A , Kramer CP, Kang Y, Gertz MA, Stuart RK, Kumar SK, Transfusion, 9/1/2013
• Can Longitudinal Strain by 2 Dimensional Speckle Tracking Echocardiography Provide Diagnostic and Prognostic Value in Immunoglobulin Light Chain and Hereditary Transth...  
  Xu YL, Dispenzieri A , Pellikka PA, Olson M, Cha S, Villarraga HR, Eur Heart J, 8/1/2013
• Use of Cmri for Prognosis of Cardiac Amyloidosis  
  Boynton S, Dispenzieri A , Syed I, Grogan M, Araoz P, Glockner J, J Am Coll Cardiol, 3/12/2013
• Electrocardiographic Findings in Transthyretin-related Cardiac Amyloidosis  
  O'Donnell E, Klarich K, Olson A, Lin G, Brady P, Dispenzieri A , Gertz M, Zeldenrust S, Grogan M, J Am Coll Cardiol, 3/12/2013
• Sensitivity of Subcutaneous Fat Aspirate Biopsy for Detection of Systemic Amyloidosis in Cardiac Biopsy-proven Transthyretin Cardiomyopathy  
  Fine NM, Olson A, Zeldenrust S, Miller F, Bielinski S, Klarich K, Dispenzieri A , Scott C, Grogan M, J Am Coll Cardiol, 3/12/2013
• Join now to see all

Books/Book Chapters

• Abeloff's Clinical Oncology 
  Chapter: Multiple Myeloma and Related Disorders 
  Page 1991 - 2017Rajkumar SV, Dispenzieri AEditors: Niederhuber JE; et al.Churchill Livingstone, PhiladelphiaEdition Fift,2014
• Multiple Myeloma: Diagnosed and Treatment 
  Chapter: POEMS Syndrome (Takatsuki Syndrome) 
  Page 179 - 193Dispenzieri AEditors: Gertz MA; Rajkumar SV.Springer, New York2014
• Myeloma-Pathology, Diagnosis, and Treatment 
  Chapter: POEMS Syndrome and Paraproteinemic Syndromes: Management and Follow-up 
  Page 225 - 243Dispenzieri A , Hayman SEditors: Schey SA, Yong KL, Marcus R, Anderson KC.Cambridge University Press, New YorkEdition 1st,2014
• Wintrobe's Clinical Hematology 
  Chapter: POEMS Syndrome, Cryoglobulinemia, and Heavy-chain Disease 
  Page 2141 - 2157Dispenzieri A , Dingli D, Gertz MAEditors: Greer JP; et al.Wolters Kluwer Health/Lippincott Williams & Wilkins, PhiladelphiaEdition Thir,2014
• Wintrobe's Clinical Hematology 
  Chapter: Multiple Myeloma 
  Page 2046 - 2097Dispenzieri A , Lacy MQ, Kumar SEditors: Greer JP; et al.Wolters Kluwer Health/Lippincott Williams & Wilkins, PhiladelphiaEdition Thir,2014
• Wintrobe's Clinical Hematology 
  Chapter: Immunoglobulin Light-chain Amyloidosis (Primary Amyloidosis) 
  Page 2098 - 2123Gertz MA, Lacy MQ, Dispenzieri A , Zeldenrust SREditors: Greer JP; et al.Wolters Kluwer Health/Lippincott Williams & Wilkins, PhiladelphiaEdition Thir,2014
• Neoplastic Diseases of the Blood 
  Chapter: Immunoglobulins and Laboratory Recognition of Monoclonal Proteins 
  Page 565 - 588Katzmann J, Kyle RA, Lust J, Snyder M, Dispenzieri AEditors: Wiernik PH; et al.Springer, New YorkEdition 5th,2013
• Clinical Immunology: Principles and Practice 
  Chapter: Monoclonal Gammopathies 
  Page 975 - 986Kyle RA, Dispenzieri AEditors: Rich RR; et al.Elsevier/Saunders, OxfordEdition 4th,2013
• Non-Hodgkin Lymphomas 
  Chapter: Diagnosis and Management of Disorders That Can Mimic Lymphoma 
  Page 557 - 585Dispenzieri A , Pittaluga S, Facchetti F, Feuillard J, Jaffe ESEditors: Armitage JO; et al.Wolters Kluwer Health/Lippincott Williams & Wilkins, PhiladelphiaEdition 2nd,2010
• Amyloidosis: Diagnosis and Treatment 
  Chapter: Assessing Response and Prognosis in AL Amyloidosis 
  Page 77 - 93Dispenzieri AEditors: Gertz MA; Rajkumar SV.Humana Press, New York2010
• Protein Misfolding Diseases: Current and Emerging Principles and Therapies 
  Chapter: Current Therapies for Light-chain Amyloidosis 
  Page 775 - 793Dispenzieri A , Kumar SEditors: Ramirez-Alvarado M; Kelly JW; Dobson CM.Wiley, Hoboken2010
• Myeloma Therapy: Pursuing the Plasma Cell 
  Chapter: Chapter 34: POEMS Syndrome and Other Atypical Plasma Cell Disorders 
  Dispenzieri ASpringer2009
• Wintrobe's Clinical Hematology 
  Chapter: Cryoglobulinemia and Heavy Chain Disease 
  Page 2484 - 2496Dispenzieri A , Gertz MA, Witzig TEEditors: Greer JP, et al.Wolters Kluwer Health/Lippincott Williams & Wilkins, PhiladelphiaEdition 12th,2009
• Treatment of Multiple Myeloma and Related Disorders 
  Chapter: Diagnosis and Treatment of POEMS Syndrome 
  Page 182 - 194Dispenzieri AEditors: Rajkumar SV, Kyle RA.Cambridge University Press, Cambridge; New York2009
• Hematology: Basic Principles and Practice 
  Chapter: Immunoglobulin Light-chain Amyloidosis (Primary Amyloidosis) 
  Page 1425 - 1447Gertz MA, Lacy MQ, Dispenzieri A , Hayman SREditors: Hoffman R, et al.Churchill Livingstone/Elsevier, PhiladelphiaEdition 5th,2009
• Non-Hodgkin Lymphomas 
  Chapter: Chapter 38: Diagnosis and Management of Disorders that Can Mimic Lymphoma 
  Dispenzieri A , Pittaluga S, Facchetti F, Feuillard J, Jaffe EEdition Seco,2009
• Encyclopedia of Molecular Mechanisms of Disease 
  Chapter: POEMS Syndrome 
  Dispenzieri A2008
• Myeloma Therapy: Pursuing the Plasma Cell 
  Chapter: POEMS Syndrome and Other Atypical Plasma Cell Disorders 
  Page 571 - 623Dispenzieri AEditors: Lonial S.Humana, Totowa2008
• Textbook of Cardiovascular Medicine 
  Chapter: Hematologic Disorders and the Heart 
  Page 604 - 612Tefferi A, Dispenzieri AEditors: Topol EJ.Lippincott Williams & Wilkins, PhiladelphiaEdition 3rd,2007
• Clinical Malignant Hematology 
  Chapter: Definition of Remission, Prognosis, and Follow-up 
  Page 913 - 926Rajkumar SV, Dispenzieri AEditors: Sekeres MA, Kalaycio ME, Bolwell BJ.McGraw-Hill Medical, New York2007
• Neurological Therapeutics: Principles and Practice 
  Chapter: Neuropathy Associated with the Monoclonal Gammopathies 
  Page 2401 - 2414Kyle RA, Dispenzieri AEditors: Noseworthy JH.Informa Healthcare, AbingdonEdition 2nd,2006
• Neurological Therapeutics: Principles and Practice 
  Chapter: Amyloidosis 
  Page 2415 - 2425Kyle RA, Dispenzieri AEditors: Noseworthy JH.Informa Healthcare, AbingdonEdition 2nd,2006
• Hematology: Basic Principles and Practice 
  Chapter: Amyloidosis 
  Page 1537 - 1560Gertz MA, Lacy MQ, Dispenzieri AEditors: Hoffman R, et al.Elsevier Churchill Livingstone, PhiladelphiaEdition 4th,2005
• Peripheral Neuropathy 
  Chapter: POEMS Syndrome (Osteosclerotic Myeloma) 
  Page 2453 - 2469Dispenzieri A , Suarez GA, Kyle RAEditors: Dyck PJ, Thomas PK.Elsevier Saunders, PhiladelphiaEdition 4th,2005
• Hematologic Malignancies: Multiple Myeloma and Related Plasma Cell Disorders 
  Chapter: Immunoglobulin Light Chain Amyloidosis (Primary Amyloidosis, AL) 
  Page 157 - 195Gertz MA, Lacy MQ, Dispenzieri AEditors: Gertz MA, Greipp PR.Springer, Berlin2004
• Join now to see all

Abstracts/Posters

• Optimal Therapy for Relapsed AL Amyloidosis Post Autologous Stem Cell Transplant
  Angela Dispenzieri, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Patient Experience of Chimeric Antigen Receptor (CAR)-T Cell Therapy Vs. Stem Cell Transplant: Longitudinal Patient Reported Adverse Events, Cognition and Quality of Life
  Angela Dispenzieri, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Glycosylation of Immunoglobulin Light Chains Is Highly Prevalent in Cold Agglutinin Disease
  Angela Dispenzieri, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• A Novel Approach to Risk Stratification in Multiple Myeloma Using ISS Stage and FISH
  Angela Dispenzieri, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Delayed Neutrophil Engraftment in Patients Receiving Daratumumab As Part of Their First Induction Regimen for Multiple Myeloma
  Angela Dispenzieri, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Impact of sFLC Ratio on Outcome in Patients with MM: Validating the Utility of sFLC in Response Definition
  Angela Dispenzieri, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Use of Maintenance Therapy Post Autologous Stem Cell Transplantation Outside of Clinical Trial Setting for Multiple Myeloma: Single Institution Experience
  Angela Dispenzieri, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Utilizing Multiparametric Flow Cytometry to Identify Patients with Primary Plasma Cell Leukemia at Diagnosis
  Angela Dispenzieri, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Waldenstr_m Macroglobulinemia with Excess Plasma Cells: Is It a Distinct Entity?
  Angela Dispenzieri, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Gene Expression Profiling of Structural and Functional High-Risk Multiple Myeloma
  Angela Dispenzieri, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Immunoglobulin Variable Gene Region (IGVL) Usage Correlates with Distinct Clinical Presentation in IgM Versus Non-IgM Light Chain Amyloidosis
  Angela Dispenzieri, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Mortality of Patients with Multiple Myeloma after the Introduction of Novel Therapies in the United States
  Angela Dispenzieri, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• A Proteomic Atlas of Cardiac Amyloidosis
  Angela Dispenzieri, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Immunoglobulin Variable Gene Region (IGVL) Usage Correlates with Distinct Clinical Presentation in IgM Versus Non-IgM Light Chain Amyloidosis
  Angela Dispenzieri, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Prognostic Implications of Serum Monoclonal Protein Positivity By Mass-Fix in Bone Marrow Minimal Residual Disease Negative (MRD-) Patients with Multiple Myeloma
  Angela Dispenzieri, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• The Impact of Socioeconomic Risk Factors on the Survival Outcomes of Patients with Newly Diagnosed Multiple Myeloma
  Angela Dispenzieri, 61st Annual American Society of Hematology Meeting, 61st Annual American Society of Hematology Meeting - Orlando, FL, 12/8/2019
• Metaphase Cytogenetics for Risk Stratification in Newly Diagnosed Multiple Myeloma
  Angela Dispenzieri, 61st Annual American Society of Hematology Meeting, 61st Annual American Society of Hematology Meeting - Orlando, FL, 12/9/2019
• The CCND1 870G Risk Allele Is Enriched in African Individuals with Plasma Cell Dyscrasias
  Angela Dispenzieri, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• The Impact of Socioeconomic Risk Factors on the Survival Outcomes of Patients with Newly Diagnosed Multiple Myeloma
  Angela Dispenzieri, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Phase 2 Trial of Daratumumab, Ixazomib, Lenalidomide and Modified Dose Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma
  Angela Dispenzieri, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Suppression of Involved Immunoglobulin Free Light Chain Post Therapy and Survival Outcomes Following Autologous Stem Cell Transplantation for Myeloma
  2013 BMT Tandem Meetings, Salt Lake City, Utah, 2/1/2013
• Redefining Engraftment Syndrome: The New Mayo Clinic Criteria
  2013 BMT Tandem Meetings, Salt Lake City, Utah, 2/1/2013
• POEMS Syndrome: More than a Medical Verse
  Henry Ford Hospital Medical Grand Rounds, 5/1/2011
• Update on Amyloidosis
  3rd Annual Canadian Conference on LPD, 3/1/2011
• A Phase III Randomized Trial of Thalidomide (THAL) Plus Zoledronic Acid (ZLD) Versus Zoledronic Acid Alone in Patients with Early Stage Multiple Myeloma
  Witzig TE, Mandrekar S, Detweiler-Short K, Lacy MQ, Laumann K, Dispenzieri A , Hayman SR, Kumar S, Reeder CB, Roy V, Lust JA, Gertz MA, Greipp PR, Rajkumar SV, Blood (ASH Annual Meeting Abstracts), 11/1/2010
• Join now to see all

Lectures

• Monoclonal Gammopathies of Cutaneous, Neuropathic, and Renal Significance 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Serum BCMA levels to predict outcomes for patients with MGUS and smoldering multiple myeloma (SMM). 
  2019 ASCO Annual Meeting - 6/1/2019
• Ixazomib, lenalidomide, and dexamethasone for patients with POEMS syndrome. 
  2019 ASCO Annual Meeting - 6/1/2019
• Longer Term Follow up of the  Randomized Phase III Trial SWOG S0777: Bortezomib, Lenalidomide and Dexamethasone Vs. Lenalidomide and Dexamethasone in Patients (Pts) w... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Mass Cytometry Identifies Immunomic Shifts in the Bone Marrow Microenvironment of Multiple Myeloma and Light Chain Amyloidosis after Standard of Care First Line Therapies 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Bortezomib, Lenalidomide and Dexamethasone (VRD) Followed By Autologous Stem Cell Transplant for Newly Diagnosed Multiple Myeloma; The Mayo Clinic Experience 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Long-Term Survivorship with Active Multiple Myeloma 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Ibrutinib Therapy in Patients with Waldenstrom Macroglobulinemia: Outcomes Outside of Clinical Trial Setting 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Development of Thrombocytopenia and Survival Outcomes in Newly Diagnosed Multiple Myeloma 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• POEMS Syndrome, 2014 and Beyond 
  Hong Kong, China - 9/1/2014
• Current Definition of Asymptomatic Myeloma 
  Milan, Italy - 6/1/2014
• POEMS Syndrome: A Case Based Approach to Evaluation and Best Management 
  Chicago, Illinois - 6/1/2014
• Measles Oncolytic Therapy 
  Boston, Massachusetts - 4/1/2014
• Benign Monoclonal Gammopathy: How Benign Is It Really? How Do We Know It? 
  Austin Court, Birmingham, United Kingdom - 3/1/2014
• Plasma Cell Clones - When to Worry. A Multidisciplinary Approach 
  Manchester, United Kingdom - 3/1/2014
• Novel Agents for Myeloma - A 2014 Update 
  Manchester, United Kingdom - 3/1/2014
• Amyloidosis: Should Our Treatment Approches Be More Personalized? When is High-Dose Chemotherapy the Best Choice 
  Grapevine, Texas - 2/1/2014
• Initial Therapy for Multiple Myeloma 
  Scottsdale, Arizona - 1/1/2014
• Phase 2 Trial Of Single Agent MLN9708 In Patients With Relapsed Multiple Myeloma Not Refractory To Bortezomib 
  New Orleans, Louisiana - 12/1/2013
• Effect Of Immedicate Prior-Line Lenalidomide Or Thalidomide Therapy On Response To Pomalidomide In Multiple Myeloma 
  New Orleans, Louisiana - 12/1/2013
• POEMS 
  Cesme, Turkey - 10/1/2013
• Management of Newly Diagnosed Multiple Myeloma 
  Cesme, Turkey - 10/1/2013
• ABMT/Tandrem Transplant in the Era of New Drugs 
  Cesme, Turkey - 10/1/2013
• Allo Transplantation in Multiple Myeloma 
  Cesme, Turkey - 10/1/2013
• AL Amyloidosis and Light-Chain Deposition Disease 
  Houston, Texas - 9/1/2013
• Join now to see all

Other

• Primary Amyloidosis 
  European School of Oncology Website
  8/1/2013
• Treatment Paradigms of Multiple Myeloma: Do Emerging Therapies Offer an Advantage 
  Live CME Certified, Satellite Broadcast
  Chicago, Illinois - 9/1/2006
• Multiple Myeloma Module 
  Dispenzieri A, PIER for the ACP
  1/1/2003